Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1958327 | 0.82 | MTNR1A (0.52) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1778405 | 0.76 | OPRM1 (0.34) | GAAALDH1A1KMT2AMPOMEN1 | |
| SCHEMBL1775879 | 0.73 | OPRM1 (0.33) | MPOSMN1; SMN2 | |
| SCHEMBL562714 | 0.71 | MTNR1A (0.57) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1958324 | 0.71 | GAA (0.59) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1776729 | 0.70 | MPO (0.53) | MAPK1MPOCYP3A4HPGD | |
| SCHEMBL1775931 | 0.70 | MPO (0.53) | MAPK1MPOCYP3A4HPGD | |
| SCHEMBL1774519 | 0.70 | MPO (0.53) | MAPK1MPOCYP3A4HPGD | |
| SCHEMBL7187029 | 0.70 | MTNR1A (0.56) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 | |
| SCHEMBL1960768 | 0.69 | GAA (0.56) | MTNR1AMTNR1BGAAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943625-B2 | Myeloperoxidase inhibitors; neuroinflammatory disorders; COPD; 3-(2-Ethoxy-2-methylpropyl)-2-thioxanthine | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| EP-2029598-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080221133-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2007142576-A1 | 2-THIOXANTHINE DERIVATIVES ACTING AS MPO-INHIBITORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131459-A1 | 2-Thioxanthine Derivatives Acting as MPO-Inhibitors | MPO, SERPINB1, XDH | MTNR1A 335/4885MTNR1B 331/4885GAA 1047/4885 |
| US-20080221133-A1 | Compounds | C1R, C1S, AKR1C3 | MTNR1A 980/4885MTNR1B 866/4885GAA 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.